Cancer Genetics, Inc. To Present Insights On Patient Stratification & Diagnostics For Immunotherapy Trials At The Companion Diagnostics (CDx) Symposium On November 2-3

  • The CDx market is expected to reach six billion US dollars by 2022 and drive significant cost savings by improving trial outcomes and enabling precision patient segmentation strategies.
  • CGI will be providing real-world insights, many in immuno-oncology trials, on implementing biomarkers into real world cancer care.

RUTHERFORD, N.J., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "The Company"), a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that it will present at the Companion Diagnostics (CDx) Symposium on November 2nd and 3rd, 2016 in Edison, NJ.

The global CDx market is projected to reach close to $6 billion by 2022, according to Global Industry Analysts, Inc. (GIA), a leading market research firm. The CDx market is expected to increase due to technological advances, increasing adoption of CDx tests by clinicians, and encouragement from regulatory authorities. Strategies for parallel development or co-development of a CDx with targeted therapeutics and immuno-oncology agents are in high demand and ensure the safe and effective use of the therapeutic products.

"We are now entering a new era of precision medicine that is marked by greater understanding of biomarker development, integration of both genomic and immune markers and a high degree of availability of precision drugs. As a result our biopharma services business has seen significant demand in CDx development, CDx validation, and CDx strategy development. CGI is developing or managing CDx programs for some of the largest pharma and IVD companies globally in cancer, which we expect will result in durable, and differentiated cancer tests and capabilities," said Panna Sharma, Chief Executive Officer and President of CGI. 

CGI's Medical Director, Boaz Kurtis, MD, will deliver a presentation covering the integration of test findings in the clinical laboratory to assist in patient segmentation, sample utilization for multiple testing modalities, and implementation of novel biomarkers. "Pathogenomic Biomarker Integration in the Immunotherapy Era: Valuable Insights from the Clinical Laboratory" will be presented on Wednesday, Nov. 2nd, at 11:35 am.

If you liked this article you might like

Liking the Look of Some of These Pullbacks

Heck With the NFL Draft; I'm Anxiously Awaiting a Big Earnings Night

Don't Be Surprised If Dip Buyers Jump In on Any Pullback

The Best Timeframe Right Now Is the Intraday Trade

Health Care Vote Impacts Trump's Deal Maker Image